Lectin approaches for glycoproteomics in FDA-approved cancer biomarkers

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 227-236

  Badr, Haitham A ^a,b,c   Alsadek, Dina M M ^a,b,d   Darwish, Ashraf A ^e   Elsayed, Abdelaleim I ^c   Bekmanov, Bakhytzhan O ^a   Khussainova, Elmira M ^a   Zhang, Xueji ^g   Cho, William C S ^f   Djansugurova, Leyla B ^a   Li, Chen Zhong ^b  

^a Institute of Genetics and Physiology   (Kazakhstan)

^b The Department of Electrical and Computer Engineering   (United States)

^c Zagazig University   (Egypt)

^d Zagazig University   (Egypt)

^e Helwan University   (Egypt)

^f QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^g UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

Author keywords

biomarkers; cancer; diagnosis; glycoproteome; lectins

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN EPIDIDYMIS PROTEIN 4; LECTIN; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR MARKER; GLYCOPROTEIN; PROTEOME;

CANCER DIAGNOSIS; COLORECTAL CANCER; FOOD AND DRUG ADMINISTRATION; GRIFFONIA; HUMAN; LENTIL; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; OVARY CANCER; PEANUT; PROSTATE CANCER; PROTEOMICS; REVIEW; THYROID CANCER; ULEX EUROPAEUS; WHEAT; WISTERIA; CHEMISTRY; METABOLISM; NEOPLASMS; UNITED STATES;

GLYCOPROTEINS; HUMANS; LECTINS; NEOPLASMS; PROTEOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84897003067     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.897611     Document Type: Review

References (81)

1. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006;6(7):565-71
2. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5(11): 845-56
3. Drake PM, Schilling B, Niles RK, et al. A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. Anal Biochem 2011;408(1): 71-85
4. Rifai N, Gerszten RE. Biomarker discovery and validation. Clin Chem 2006;52(9): 1635-7
5. Poste G. Bring on the biomarkers. Nature 2011;469(7329):156-7
6. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452(7187):571-9
7. Dennis JW, Nabi IR, Demetriou M. Metabolism, cell surface organization, and disease. Cell 2009;139(7):1229-41
8. Ohtsubo K, Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006;126(5):855-67
9. Clark D, Mao L. Cancer biomarker discovery: lectin-based strategies targeting glycoproteins. Dis Markers 2012;33(1):1-10
10. Hart GW, Copeland RJ. Glycomics hits the big time. Cell 2010;143(5):672-6
11. Cunningham S, Gerlach JQ, Kane M, Joshi L. Glyco-biosensors: recent advances and applications for the detection of free and bound carbohydrates. Analyst 2010; 135(10):2471-80
12. Lin Z, Lubman DM. Permethylated N-glycan analysis with mass spectrometry. In: Matthiesen R, editor. Mass spectrometry data analysis in proteomics. Volume 1007 Humana Press; Newyork, NY, USA: 2013. p. 289-300
13. Rillahan CD, Paulson JC. Glycan microarrays for decoding the glycome. Annu Rev Biochem 2011;80:797-823
14. Agard NJ, Bertozzi CR. Chemical approaches to perturb, profile, and perceive glycans. Acc Chem Res 2009;42(6):788-97
15. Vark A, Cummings RD, Esko JD, et al. Essentials of glycobiology. Cold Spring Harbor Laboratory Press; Cold Springer Harbor, NY: 2009
16. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379(9822):1245-55
17. Liu Y, He J, Li C, et al. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res 2010;9(2):798-805
18. Ichikawa E, Kuriyama S, Yuji J, et al. Further resolution of alpha-fetoprotein glycoforms by two-dimensional isoelectric focusing and lectin affinity electrophoresis. Electrophoresis 2006;27(17):3480-7
19. Eiji MKM, Naoko T, Cheng-Cheng T, et al. Fucosylation is a promising target for cancer diagnosis and therapy. Biomolecules 2012;2(1):34-45
20. Kagebayashi C, Yamaguchi I, Akinaga A, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388(2): 306-11
21. Ito H, Kuno A, Sawaki H, et al. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J Proteome Res 2009;8(3): 1358-67
22. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10(4):211-24
23. Wang Y, Wu R, Cho KR, et al. Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res 2009;8(3):1452-63
24. Karlsen MA, Sandhu N, Hogdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127(2): 379-83
25. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10(5): 371-8
26. Wu J, Xie X, Liu Y, et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res 2012; 11(9):4541-52
27. Tian E, Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J 2009;26(3): 325-34
28. Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 2011;55:1-20
29. Kadija S, Stefanovic A, Jeremic K, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22(2):238-44
30. Saldova R, Struwe WB, Wynne K, et al. Exploring the glycosylation of serum CA125. Int J Mol Sci 2013;14(8):15636-54
31. Weiland F, Martin K, Oehler MK, et al. Deciphering the molecular nature of ovarian cancer biomarker CA125. Int J Mol Sci 2012;13(8):10568-82
32. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65(6):2162-9
33. Kuzmanov U, Musrap N, Kosanam H, et al. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clin Chem Lab Med 2013;51(7):1467-76
34. Biskup K, Braicu EI, Sehouli J, et al. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. J Proteome Res 2013; 12(9):4056-63
35. Bouanene H, Miled A. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16. Dis Markers 2010;28(6):385-94
36. Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 2012;31(3-4):501-18
37. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed 2011; 50(8):1770-91
38. Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008;4(1):35-42
39. Chen K, Gentry-Maharaj A, Burnell M, et al. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res 2013;12(3): 1408-18
40. Tachibana K, Nakamura S, Wang H, et al. Elucidation of binding specificity of Jacalin toward O-glycosylated peptides: quantitative analysis by frontal affinity chromatography. Glycobiology 2006;16(1):46-53
41. Wu AM, Wu JH, Yang Z, et al. Differential contributions of recognition factors of two plant lectins, Amaranthus caudatus lectin and Arachis hypogea agglutinin, reacting with Thomsen- Friedenreich disaccharide (Galb1- 3GalNAca1-Ser/Thr). Biochimie 2008; 90(11-12):1769-80
42. Yin BW, Finstad CL, Kitamura K, et al. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 1996;65(4):406-12
43. Zhuang H, Gao J, Hu Z, et al. Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One 2013;8(7): e68994
44. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143(6):725-9
45. Noble P, Spendlove I, Harding S, et al. Therapeutic targeting of Lewis y and Lewis b with a novel monoclonal antibody 692/
46. Yuan J, Duan R, Yang H, et al. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance. Int J Nanomedicine 2012;2012(7):2921-8
47. Liu C, Lei T, Ino K, et al. Real-time monitoring biomarker expression of carcinoma cells by surface plasmon resonance biosensors. Chem Commun 2012;48(84):10389-91
48. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381(9871):1058-69
49. McIver B. Postoperative surveillance of thyroid carcinoma. Oral Oncol 2013;49(7): 684-8
50. Latrofa F, Ricci D, Montanelli L, et al. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. J Clin Endocrinol Metab 2012;97(7):2380-7
51. Suh I, Vriens MR, Guerrero MA, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg 2010;200(1):41-6
52. Petric R, Perhavec A, Gazic B, Besic N. Preoperative serum thyroglobulin concentration is an independent predictive factor of malignancy in follicular neoplasms of the thyroid gland. J Surg Oncol 2012; 105(4):351-6
53. Yang SX, Pollock HG, Rawitch AB. Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch Biochem Biophys 1996; 327(1):61-70
54. Sinadinovic J, Cvejic D, Savin S, et al. Altered terminal glycosylation of thyroglobulin in papillary thyroid carcinoma. Exp Clin Endocrinol 1992; 100(3):124-8
55. Rosenfeld R, Bangio H, Gerwig GJ, et al. A lectin array-based methodology for the analysis of protein glycosylation. J Biochem Biophys Methods 2007;70(3):415-26
56. Takeya A, Hosomi O, Nishijima H, et al. Presence of beta-linked GalNAc residues on N-glycans of human thyroglobulin. Life Sci 2007;80(6):538-45
57. Martin SK, Vaughan TB, Atkinson T, et al. Emerging biomarkers of prostate cancer. Oncol Rep 2012;28(2):409-17
58. Velonas VM, Woo HH, Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci 2013; 14(6):11034-60
59. Bhavsar T, McCue P, Birbe R. Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol 2013;40(3):259-75
60. Tabares G, Radcliffe CM, Barrabes S, et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006; 16(2):132-45
61. Mattsson JM, Valmu L, Laakkonen P, et al. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 2008;68(9):945-54
62. Sarrats A, Saldova R, Comet J, et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS 2010;14(4):465-74
63. White KY, Rodemich L, Nyalwidhe JO, et al. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res 2009;8(2):620-30
64. Meany DL, Zhang Z, Sokoll LJ, et al. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res 2009;8(2):613-19
65. Kuno A, Kato Y, Matsuda A, et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol Cell Proteomics 2009;8(1):99-108
66. Gilgunn S, Conroy JP, Saldova R, et al. Aberrant PSA glycosylation-a sweet predictor of prostate cancer. Nat Rev Urol 2013;10:99-107
67. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60: 277-300
68. Jeon BG, Shin R, Chung JK, et al. Individualized cutoff value of the preoperative carcinoembryonic antigen level is necessary for optimal use as a prognostic marker. Ann Coloproctol 2013;29(3): 106-14
69. Palermo NY, Thomas P, Murphy RF, Lovas S. Hexapeptide fragment of carcinoembryonic antigen which acts as an agonist of heterogeneous ribonucleoprotein M. J Pept Sci 2012;18(4):252-60
70. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008;57(12):1879-90
71. Ahn YH, Ji ES, Shin PM, et al. A multiplex lectin-channel monitoring method for human serum glycoproteins by quantitative mass spectrometry. Analyst 2012;137(3): 691-703
72. Dam TK, Cavada BS, Nagano CS, et al. Fine specificities of two lectins from Cymbosema roseum seeds: a lectin specific for high-mannose oligosaccharides and a lectin specific for blood group H type II trisaccharide. Glycobiology 2011;21(7): 925-33
73. Zhao YP, Ruan CP, Wang H, et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer 2012;118(3): 639-50
74. Jokerst JV, Raamanathan A, Christodoulides N, et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009;24(12):3622-9
75. Kaneshiro K, Watanabe M, Terasawa K, et al. Rapid quantitative profiling of N-glycan by the glycan-labeling method using 3-aminoquinoline/a-cyano-4- hydroxycinnamic acid. Anal Chem 2012; 84(16):7146-51
76. Song W, Delyria ES, Chen J, et al. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol 2012; 41(6):1977-84
77. Blixt O, Boos I, Mandel U. Glycan microarray analysis of tumor-associated antibodies. In: Kosma P, editor. Anticarbohydrate antibodies. Springer Verlag; New York: 2012
78. Garrett JT, Rawale S, Allen SD, et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178(11):7120-31
79. Chandler K, Goldman R. Glycoprotein disease markers and single protein-omics. Mol Cell Proteomics 2013;12(4):836-45
80. Drake PM, Cho W, Li B, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010;56(2):223-36
81. Badr HA, Elsayed AI, Ahmed H, et al. Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient deprivation. Appl Biochem Biotechnol 2013;71(4):963-74